Date: 2014-09-30
Type of information: Collaboration agreement
Compound:
Company: The Lead Discovery Center (LDC) (Germany) Helmholtz Association (Germany)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism:
Disease: neuroblastoma and other cancer types
Details: * On September 30, 2014, The Lead Discovery Center GmbH and the Helmholtz Association, Germany’s biggest scientific organization, will be collaborating more closely in future. An initial pilot project in cooperation with Prof. Schulte’s research group at the DKTK partner site Essen/Dusseldorf has just been launched. Together with the LDC, they will be developing a novel cancer therapy approach with the aim of identifying new drug candidates for the treatment of neuroblastoma and other cancer types. As part of the cooperation, the partners intend to identify and validate initial drug candidates from LDC’s compound library. In parallel, the LDC will use its industry contacts to win potential pharmaceutical partners in good time for subsequent clinical development. The LDC and the Helmholtz Association already have their sights set on further collaborations. In order to translate innovative approaches into application, the Helmholtz Association is supporting selected projects via the Helmholtz Validation Fund (HVF). The Helmholtz Association is Germany’s biggest scientific organization, comprising several centres internationally recognized for their top-level health research, including the German Cancer Research Center (DKFZ), the DKTK’s core centre.
Financial terms:
Latest news:
